Rhonda Q. Freeman, Ph.D.
rfreeman@smgumc.com

Neuropsychologist with a special interest in the evaluation and treatment of cognitive and psychological disorders. Particular interest in adult ADHD, Alzheimer’s disease, dementia, memory loss, head injury, depression and anxiety.

PROFESSIONAL AND TEACHING ACTIVITIES

[2001-present] Sunrise Medical Group, Broward County, Florida

[2002-present] Sunrise Clinical Research, Hollywood, Florida

[2001-present] Forensic & Clinical Psychology Associates, Miami, FL

[2002-present] Memorial Hospital-Pembroke — Memory Disorder Center

[2001] The Center for Psychology & Neuropsychiatry Rehabilitation

[1992-1997] Northwestern Institute of Psychiatry, Fort Washington, PA

[1999-2000] Give Neuropsychological Lectures and Labs at Mt. Sinai Medical Center, Miami Beach, FL

[1997] Philadelphia College of Osteopathic Medicine, Philadelphia, PA, Guest Lecturer Neuroanatomy

[1993-1994] Drexel University, Philadelphia, PA, Taught basic research skills

MEDICAL DEGREE

[1999] Drexel University, Philadelphia, PA, Ph.D in Clinical Psychology

CERTIFICATIONS, QUALIFICATIONS AND APPOINTMENTS

[1992] Drexel University, Philadelphia, PA, Bachelor of Science

[1996] Drexel University, Philadelphia, PA, Master of Science

GRADUATE TRAINING

Post Doctoral Fellowship: Neuropsychology

[1999-2000] (University of Miami School of Medicine: Wien Center for Memory Disorders and Alzheimer’s disease, Mt. Sinai Medical Center, Neurology and Neuropsychology, Research in dementia and Neuropsychology, Published. Miami Beach, FL)

Internship: Psychology

[1997-1998] (Norristown State Hospital, Norristown, PA)

[1997-1998] (Philadelphia Geriatric Center, Philadelphia, PA)

Clinical Training: Neuropsychology

[1998-1999] (Neurobehavioral Unit- Riddle Memorial Hospital, Media, PA)

 AFFILIATED ASSOCIATIONS

Florida Psychological Association, Board Member- Ethnic Minority

RESEARCH, PRESENTATIONS, PUBLISHED BOOKS AND PAPERS

[2001] Loewenstein, DA., Arguelles, S., Bravo, M., Freeman, RO., Arguelles, T., Acevedo, A., & Eisdorfer, C. Caregivers’ Judgments of the Functional Abilities of the Alzheimer’s Disease Patient: A Comparison of Proxy Reports and Objective Measures of the Functional Status, Journal of Gerontology

[in press] Loewenstein, IDA, Arguelies, T., Barker, W., Acevedo, A., Freeman, RQ, Schram, L. Ownby, RL, White, G., Mogosky, BJ, & Duara, R. The Utility of a Modified Object Memory Test in Distinguishing Between Different Age Groups of Alzheimer’s Disease Patients and Normal Controls. Journal of Gerontology

[200] Freeman, RO., Giovanetti, T., Lamar, M., Cloude, B., Stern, R., Kaplan E., & Libon, D. Visuoconstructional Problems in Dementia: Contribution of Executive Systems Functions. Neuropsychology

Behavioral Modification & the Neurologically Impaired, The Rehabilitation Hospital at Lee Memorial Hospital

[2001] Rehabilitation Psycholology, The Rehabilitation Hospital at Lee Memorial Hospital

[2000] Freeman, RO., Loewenstein, CA, Acevedo, A., & Schram, L. Intrusion Errors in Learning & Memory: A comparison of Alzheimer’s Disease and Vascular Dementia. Poster Presented at the National Academy of Neuropsychology, Orlando, Florida

[2000] Visuoconstructional Impairment in Dementia. University of Miami School of Medicine-Jackson Memorial Hospital-Neuropsychology Rounds

[1999] Neuropsychological Seguelea of Cardiac Disease. University of Miami School of Medicine-Jackson Memorial Hospital-Neuropsychology Rounds

[2000] Are there Neurobehavioral Markers in Alzheimer’s Disease. University of Miami School of Medicine-Jackson Memorial Hospital-Neuropsychology Rounds

“A Fourteen-Week Placebo­ Controlled, Multicenter, Safety and Efficacy Evaluation of Three Doses of XX-X) O (in Patients with Mild to Moderate Dementia of the Alzheimer’s Type”

“A Fourteen-Week Placebo-Controlled Dose-Response Efficacy and Safety Study of XX- XXXX in Early Parkinson’s Disease Patients (study for Proof of Concept in Early Parkinson’s Disease of a Triple Reuptake Inhibitor, NS 233/SCEPTRE)

“A dose-ranging, placebo ­controlled study of XXXX.XXXX­XX at the dose of 0.5 mg, 2mg and 8mg for 12 weeks in patients with mild-to-moderate Alzheimer’s Disease patients with mild-to-moderate Alzheimer’s Disease”

“A Randomized, Double Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of XX-XXXX 25mg in Slowing the Progression of Alzheimer’s Disease”

“A ONE YEAR, MULITCENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED EVALUATION OF THE EFFICACY AND SAFETY OF DON EPEZIL HYDROCHLORIDE (XXXXX) IN SUBJECTS WITH MILD COGNITIVE IMPAIRMENT”

“A RANDOMIZED, DOUBLE­BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP PHASE 2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF XXXXX IN SUBJECTS WITH MILD TO MODERATE ALZHEIMER’S DISEASE”

“Phase 3 Multicenter, Randomized, Double Blind, Placebo Controlled Study of the Effect of Daily Treatment with XXX XXX on Measures of Cognitive and Global Function in Subjects with Mild to

Moderate Dementia of the Alzheimer’s Type”

“A randomized, multi-center, double-blind, placebo-controlled, 18-month study of the efficacy of Xaliproden in patients with mild-to-moderate dementia of the Alzheimer’s type”

“An Open-label Exploratory Study with Memantine of Selected Measures of Volumetric MRI and Cognition in Patients with Moderate Dementia of the Alzheimer’s Type”

“SAFETY, TOLERABILITY, AND EFFICACY STUDY OF ORAL KETASYN (AC-i 202) ADMINISTERED FOR NINETY DAYS IN SUBJECTS WITH PROBABLE ALZHEIMER’S DISEASE OF MILD TO MODERATE SERVERTIY”